F16, a Mitochondriotoxic Compound, Triggers Apoptosis or Necrosis Depending on the Genetic Background of the Target Carcinoma Cell

Mutations that lead to the emergence of resistance to apoptosis are commonly observed among tumor cells. Some of the proteins affected are integral parts of the apoptotic cascade such as pro- and antiapoptotic members of the Bcl-2 family. F16 is a small molecule that accumulates in mitochondria of a variety of tumor cells and interferes with their physiological function. Because this interference ultimately triggers apoptosis in many affected cell lines, we examined the effect of antiapoptotic Bcl-2 overexpression on the response of cells to F16. Our results showed that high levels of Bcl-2 did not block the ability of F16 to induce cell death. However, unlike the apoptotic response that followed F16 treatment of cells with moderate Bcl-2 levels, cells resistant to a variety of apoptotic stimuli by virtue of Bcl-2 overexpression succumbed to F16 by necrosis. Thus, this dual ability of the mitochondriotoxic compound F16 to induce apoptosis and necrosis may represent an added advantage by expanding its spectrum of action toward genetically altered tumor cells incapable of apoptosis.

[1]  P. Nicotera,et al.  Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.

[2]  J. Modica-Napolitano,et al.  Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. , 2001, Advanced drug delivery reviews.

[3]  L. B. Chen,et al.  Mitochondrial membrane potential in living cells. , 1988, Annual review of cell biology.

[4]  G. Kroemer,et al.  Genetic analysis of the mammalian cell death machinery. , 2002, Trends in genetics : TIG.

[5]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[6]  A. Nègre-Salvayre,et al.  Bcl‐2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[8]  V. Gabai,et al.  Necrosis: a specific form of programmed cell death? , 2003, Experimental cell research.

[9]  G. Kroemer.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[10]  P. Leder,et al.  The oncogene heregulin induces apoptosis in breast epithelial cells and tumors , 1998, Oncogene.

[11]  John Calvin Reed,et al.  Dysregulation of apoptosis genes in hematopoietic malignancies , 2002, Oncogene.

[12]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[13]  G. Chinnadurai,et al.  Modulation of Mitochondrial Ca2+ Homeostasis by Bcl-2* , 1999, The Journal of Biological Chemistry.

[14]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[15]  I. Summerhayes,et al.  Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Scorrano,et al.  Mitochondria and cell death. Mechanistic aspects and methodological issues. , 1999, European journal of biochemistry.

[17]  C C Ling,et al.  Radiation-induced apoptosis: relevance to radiotherapy. , 1995, International journal of radiation oncology, biology, physics.

[18]  John T. Wei,et al.  BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. , 1999, The Journal of urology.

[19]  Luca Scorrano,et al.  A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.

[20]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[21]  W. Kolch,et al.  Comparison of anthracycline-induced death of human leukemia cells: Programmed cell death versus necrosis , 2002, Apoptosis.

[22]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[23]  Luca Scorrano,et al.  Mitochondria and cell death. Mechanistic aspects and methodological issues. , 1999, European journal of biochemistry.

[24]  B. Robinson,et al.  Mitochondria, oxygen free radicals, and apoptosis. , 2001, American journal of medical genetics.

[25]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[26]  G. Núñez,et al.  Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. , 1997, Blood.

[27]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[28]  D. Green,et al.  The central executioners of apoptosis: caspases or mitochondria? , 1998, Trends in cell biology.

[29]  E. Estey,et al.  The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells , 2002, British journal of haematology.

[30]  N. Bander,et al.  Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. , 1999, Cancer research.

[31]  B. Krammer,et al.  Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. , 1999, Journal of immunology.

[32]  P. Bernardi,et al.  On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. , 1995, Toxicology.

[33]  S. Korsmeyer,et al.  Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[35]  G. Kroemer,et al.  The mitochondrial death/life regulator in apoptosis and necrosis. , 1998, Annual review of physiology.

[36]  G. Kroemer,et al.  Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. , 1997, Cancer research.

[37]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[38]  G. Kroemer,et al.  Mitochondria, the killer organelles and their weapons , 2002, Journal of cellular physiology.

[39]  G. Kroemer,et al.  The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. , 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[40]  Y. Tsujimoto,et al.  Intracellular ATP levels determine cell death fate by apoptosis or necrosis. , 1997, Cancer research.

[41]  John Calvin Reed.  Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Oberley,et al.  Induction of superoxide dismutase and cytotoxicity by manganese in human breast cancer cells. , 1999, Archives of biochemistry and biophysics.

[43]  D. Newmeyer,et al.  Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.

[44]  A. Degterev,et al.  The channel of death , 2001, The Journal of cell biology.

[45]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.